EGFR and non-small cell lung carcinoma: In addition, many targeted drugs used to treat NSCLC (e.g., EGFR-TKI and ALK-TKI), although they can prolong the survival of patients with advanced disease, the resistance of these drugs limits their long-term efficacy [10, 11].